There are 119 resources available
3P - Targeting pancreatic adenocarcinoma upregulated factor (PAUF) to treat pancreatic cancer (PC): In vivo efficacy and safety of PBP1510, a first in class monoclonal antibody (mAb)
Presenter: Sumita Pradhan
Session: e-Poster Display session
4P - Antitumor efficacy of integrin _V_3 Antibody conjugated ZnO Nanocarrier based Drug Delivery System to target Breast carcinoma
Presenter: Karuppaiya Vimala
Session: e-Poster Display session
8P - Pharmacokinetic (PK) profile and food effect of RP-3500, a highly potent and specific inhibitor of ataxia telangiectasia and Rad3-related (ATR) protein kinase in patients (pts) with cancer
Presenter: Stephanie Lheureux
Session: e-Poster Display session
9P - Preliminary population pharmacokinetic (popPK) co-variates and exposure response (ER) assessment of QT for RP-3500, a highly potent and specific inhibitor of ataxia telangiectasia and Rad3-related (ATR) protein kinase
Presenter: Elizabeth Lee
Session: e-Poster Display session
10P - SKLB-0322, a novel EZH2 covalent inhibitor, exerts potent anti-tumor activity in ovarian cancer
Presenter: Yongxia Zhu
Session: e-Poster Display session
11P - Novel HDAC6 inhibitors show anti-lymphoma activity alone and in combination with venetoclax and copanlisib
Presenter: Afua Mensah
Session: e-Poster Display session
12P - Circulating tumor DNA as early marker of response to treatment in stage IV gastrointestinal cancer
Presenter: Patrick Kirchweger
Session: e-Poster Display session
13P - Transcriptional Profiling of FET-rearranged sarcomas in response to SP-2577
Presenter: Galen Rask
Session: e-Poster Display session
14P - A novel small molecule METTL3 inhibitor exerts promising antitumor effects on oral squamous cell carcinoma
Presenter: Paramasivam Arumugam
Session: e-Poster Display session
15P - STELLAR-001: a phase 1 study of the anti-C5aR avdoralimab in combination with the anti-PD-L1 durvalumab in advanced solid tumors.
Presenter: Jaafar Bennouna
Session: e-Poster Display session